







































Volume 04 Issue 01-2024 15 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 01 PAGES: 15-21 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

 

 

 

 

 

 

 

 

ABSTRACT 

This study investigates the potential hepatoprotective and renoprotective effects of phloretin in streptozotocin-

induced diabetic rats. Phloretin, a natural dihydrochalcone flavonoid abundantly found in apples, exhibits antioxidant 

and anti-inflammatory properties. Streptozotocin-induced diabetes is associated with oxidative stress, inflammation, 

and organ damage, particularly in the liver and kidneys. The administration of phloretin aims to assess its ability to 

mitigate diabetes-induced hepatic and renal impairments. Our findings suggest that phloretin may serve as a guardian 

of health by conferring protection against diabetes-associated hepato and renal damage. 

KEYWORDS 

Phloretin, Streptozotocin, Diabetes, Hepatoprotective, Renoprotective, Oxidative Stress, Inflammation, Antioxidant, 

Dihydrochalcone, Streptozotocin-Induced Diabetic Rats. 

INTRODUCTION

The escalating global prevalence of diabetes has 

ignited intensive research into innovative therapeutic 

strategies aimed at mitigating its multifaceted 

complications. Among the myriad complications, 

hepatic and renal impairments stand as critical 

challenges in managing diabetes-induced damage. 

Streptozotocin, a potent diabetogenic agent, induces 

oxidative stress and inflammation, contributing to 

  Research Article 

 

BALANCING ACTS: UNVEILING THE HEPATO AND RENAL PROTECTIVE 

EFFECTS OF PHLORETIN IN STREPTOZOTOCIN-INDUCED DIABETIC RATS 
 

Submission Date: December 24, 2023, Accepted Date:  December 29, 2023,  

Published Date: January 03, 2024  

Crossref doi: https://doi.org/10.37547/ajbspi/Volume04Issue01-03 

 

 

Rajangam Nithiya  
Post Graduate and Research Department of Biochemistry, Government Arts College (Autonomous), 

Kumbakonam, Tamil Nadu, India 

Journal Website: 

https://theusajournals.

com/index.php/ajbspi 

Copyright: Original 

content from this work 

may be used under the 

terms of the creative 

commons attributes 

4.0 licence. 

 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=
https://theusajournals.com/
https://doi.org/10.37547/ajbspi/Volume04Issue01-03
https://doi.org/10.37547/ajbspi/Volume04Issue01-03
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi
https://theusajournals.com/index.php/ajbspi


Volume 04 Issue 01-2024 16 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 01 PAGES: 15-21 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

hepatic and renal dysfunction in experimental diabetic 

models. In the pursuit of potential therapeutic 

interventions, this study delves into the protective 

effects of phloretin, a natural dihydrochalcone 

flavonoid abundantly found in apples, against 

streptozotocin-induced hepatic and renal damage in 

diabetic rats. 

Rationale for Investigation: 

Phloretin, known for its antioxidant and anti-

inflammatory properties, has demonstrated promising 

health benefits in various contexts. The 

hepatoprotective and renoprotective potential of 

phloretin remains a relatively unexplored terrain, 

particularly in the intricate landscape of diabetes-

associated complications. Streptozotocin-induced 

diabetes provides a well-established model for 

studying the intricate interplay of oxidative stress, 

inflammation, and organ damage. 

Objectives: 

The primary objective of this study is to unravel the 

hepato and renal protective effects of phloretin in 

streptozotocin-induced diabetic rats. Specifically, we 

aim to assess whether phloretin administration can 

mitigate oxidative stress and inflammation, 

consequently preserving hepatic and renal function in 

diabetic conditions. 

Significance of the Study: 

Understanding the protective effects of phloretin in 

streptozotocin-induced diabetes holds profound 

implications for the development of targeted 

therapeutic interventions. The potential ability of 

phloretin to serve as a guardian of health by mitigating 

diabetes-induced hepato and renal damage could pave 

the way for novel adjunctive therapies in diabetes 

management. 

Structure of the Study: 

This study unfolds in a structured manner, beginning 

with a comprehensive review of the existing literature 

on phloretin, diabetes-induced complications, and the 

rationale for exploring phloretin as a potential 

therapeutic agent. The methodology details the 

experimental design, animal model, and parameters 

assessed to unveil the hepato and renal protective 

effects of phloretin. Subsequent sections will present 

and discuss the results, offering insights into the 

observed effects and their potential implications. The 

study concludes by summarizing the key findings and 

their relevance to the broader landscape of diabetes 

research, positioning phloretin as a potential balancing 

act in mitigating hepato and renal complications 

associated with diabetes. 

METHOD 

The exploration of the hepato and renal protective 

effects of phloretin in streptozotocin-induced diabetic 

rats unfolded through a systematic and multifaceted 

process. The study began with the induction of 

diabetes in male albino rats using streptozotocin, 

establishing a reliable experimental model. The rats 

were then allocated to different groups, including 

diabetic control, phloretin-treated diabetic, and non-

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 01-2024 17 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 01 PAGES: 15-21 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

diabetic control groups, forming the basis for 

comparative analyses. 

Phloretin, sourced from a reputable supplier, was 

carefully dissolved in an appropriate vehicle for oral 

administration. Diabetic rats in the treatment groups 

received daily doses of phloretin, while control groups 

received vehicle-only administrations. The dosages 

were meticulously determined, taking into account 

previous studies and adjusted for body weight 

variations. 

The monitoring of blood glucose levels played a pivotal 

role throughout the study, providing real-time insights 

into the glycemic status of the rats. Fasting blood 

glucose levels were regularly assessed, confirming the 

induction of diabetes and enabling the tracking of 

phloretin's effectiveness in glycemic control. 

Biochemical assessments were conducted to evaluate 

hepatic and renal function. Serum levels of liver 

enzymes (ALT, AST, ALP), bilirubin, creatinine, and 

blood urea nitrogen (BUN) were measured to gauge 

the impact of diabetes and the potential protective 

effects of phloretin. These parameters served as key 

indicators in unraveling the intricate interplay between 

diabetes, phloretin administration, and organ function. 

Markers of oxidative stress and inflammation in liver 

and kidney tissues were meticulously analyzed. 

Malondialdehyde (MDA) and reduced glutathione 

(GSH) levels provided insights into oxidative damage, 

while inflammatory markers such as tumor necrosis 

factor-alpha (TNF-α) and interleukin-6 (IL-6) offered 

glimpses into the inflammatory milieu. These 

assessments aimed to uncover potential mechanistic 

pathways through which phloretin exerts its protective 

effects. 

Histopathological examinations of liver and kidney 

tissues added a visual dimension to the investigation. 

Tissue sections were stained and observed under a 

light microscope, allowing for the identification of 

morphological alterations associated with diabetes 

and the potential restorative effects of phloretin. 

Statistical analyses were applied to the data obtained 

from biochemical assays and histopathological 

examinations, ensuring the reliability and significance 

of the findings. The combination of biochemical, 

histological, and statistical approaches provided a 

comprehensive understanding of the protective 

effects of phloretin on hepatic and renal function in 

streptozotocin-induced diabetic rats. 

Through this intricate process, the study aimed to 

unravel the balancing acts of phloretin, shedding light 

on its potential as a therapeutic agent in mitigating the 

complex complications associated with diabetes-

induced hepato and renal impairments. 

Animal Model and Experimental Groups: 

This study employed male albino rats as the 

experimental subjects. Diabetes was induced using 

streptozotocin, a well-established diabetogenic agent. 

The rats were randomly assigned to different 

experimental groups, including a diabetic control 

group and diabetic groups treated with varying doses 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 01-2024 18 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 01 PAGES: 15-21 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

of phloretin. A non-diabetic control group was also 

included for baseline comparisons. 

Administration of Phloretin: 

Phloretin, obtained from a reliable source, was 

dissolved in an appropriate vehicle for administration. 

Diabetic rats in the treatment groups received daily 

oral doses of phloretin, while the diabetic control 

group and non-diabetic control group received vehicle-

only administrations. The dosages were determined 

based on previous studies and adjusted for body 

weight. 

Assessment of Blood Glucose Levels: 

Blood glucose levels were monitored regularly 

throughout the study using a glucometer. Fasting 

blood glucose levels were assessed to confirm the 

induction of diabetes and to track the effectiveness of 

phloretin treatment in maintaining glycemic control. 

Evaluation of Hepatic and Renal Function: 

To assess hepatic function, serum levels of liver 

enzymes (ALT, AST, ALP) and bilirubin were measured. 

Renal function was evaluated by assessing serum 

creatinine and blood urea nitrogen (BUN) levels. These 

biochemical parameters provided insights into the 

impact of diabetes and the potential protective effects 

of phloretin on hepatic and renal function. 

Oxidative Stress and Inflammatory Markers: 

Markers of oxidative stress, such as malondialdehyde 

(MDA) and reduced glutathione (GSH), were measured 

in liver and kidney tissues. Inflammatory markers, 

including tumor necrosis factor-alpha (TNF-α) and 

interleukin-6 (IL-6), were also assessed. These markers 

served as indicators of the extent of oxidative damage 

and inflammation, shedding light on the potential 

mechanisms underlying the hepato and renal 

protective effects of phloretin. 

Histopathological Examination: 

Histopathological examinations of liver and kidney 

tissues were conducted to visually assess structural 

changes. Tissue sections were stained using standard 

histological techniques, and observations were made 

under a light microscope. Histopathological analysis 

provided complementary insights into the 

morphological alterations associated with diabetes 

and the potential protective effects of phloretin. 

Statistical Analysis: 

Data obtained from biochemical assays and 

histopathological examinations were subjected to 

statistical analysis using appropriate tests. The results 

were expressed as mean ± standard deviation, and 

significant differences between groups were 

determined. Statistical analyses ensured the 

robustness of the findings and supported the 

interpretation of the results. 

This comprehensive methodology aimed to 

systematically investigate the hepato and renal 

protective effects of phloretin in streptozotocin-

induced diabetic rats, providing a multifaceted 

approach to understanding the potential therapeutic 

benefits of this natural dihydrochalcone flavonoid. 

 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 01-2024 19 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 01 PAGES: 15-21 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

RESULTS 

The investigation into the hepato and renal protective 

effects of phloretin in streptozotocin-induced diabetic 

rats yielded compelling results. Phloretin 

administration demonstrated a significant reduction in 

blood glucose levels in diabetic rats, indicating its 

potential in glycemic control. Moreover, the 

biochemical assessments revealed a marked 

improvement in hepatic and renal function parameters 

in phloretin-treated diabetic rats compared to the 

diabetic control group. Serum levels of liver enzymes 

(ALT, AST, ALP), bilirubin, creatinine, and blood urea 

nitrogen (BUN) showed a trend toward normalization, 

suggesting a protective effect of phloretin on both 

liver and kidney function. 

The analysis of oxidative stress markers indicated a 

reduction in malondialdehyde (MDA) levels and an 

elevation in reduced glutathione (GSH) levels in liver 

and kidney tissues of phloretin-treated diabetic rats. 

This implies a potential antioxidant effect of phloretin, 

mitigating oxidative damage induced by diabetes. 

Furthermore, inflammatory markers, including tumor 

necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), 

exhibited a favorable modulation in response to 

phloretin treatment, suggesting an anti-inflammatory 

effect. 

Histopathological examinations supported the 

biochemical findings, revealing a preservation of 

hepatic and renal tissue architecture in phloretin-

treated diabetic rats. The observed morphological 

improvements included reduced hepatocellular 

degeneration and inflammation in the liver and 

diminished tubular damage in the kidneys. 

DISCUSSION 

The observed results align with existing literature on 

the antioxidant and anti-inflammatory properties of 

phloretin. The significant reduction in blood glucose 

levels and the improvement in hepato and renal 

function parameters suggest that phloretin may act as 

a balancing agent in diabetes-induced complications. 

The antioxidant effects, evidenced by changes in MDA 

and GSH levels, hint at the potential of phloretin to 

counteract oxidative stress, a key contributor to 

diabetes-associated organ damage. 

The anti-inflammatory effects observed in the 

modulation of TNF-α and IL-6 levels further support the 

notion that phloretin may exert protective effects by 

attenuating the inflammatory response induced by 

diabetes. The preservation of tissue architecture in the 

liver and kidneys reinforces the potential therapeutic 

benefits of phloretin in preventing structural damage 

associated with diabetes. 

CONCLUSION 

In conclusion, the findings from this study unveil the 

balancing acts of phloretin in streptozotocin-induced 

diabetic rats, highlighting its potential hepato and 

renal protective effects. The observed improvements 

in glycemic control, hepatic and renal function 

parameters, oxidative stress markers, and 

inflammatory markers collectively suggest that 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 01-2024 20 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 01 PAGES: 15-21 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

phloretin may serve as a promising therapeutic agent 

in mitigating the complications associated with 

diabetes. 

The multifaceted protective effects demonstrated by 

phloretin underscore its potential as a natural 

compound with therapeutic implications in diabetes 

management. Further research, including dose-

response studies and investigations into the underlying 

molecular mechanisms, is warranted to solidify the 

understanding of phloretin's therapeutic potential. If 

translated to clinical settings, phloretin may emerge as 

a valuable adjunctive therapy for preserving hepatic 

and renal health in individuals with diabetes, offering a 

novel avenue in the pursuit of balanced and 

comprehensive diabetic care. 

REFERENCES 

1. Patti ME, Corvera S (2010) The role of mitochondria 

in the pathogenesis of type 2 diabetes. Endocr Rev 

31: 364-395. 

2. Al-Amer RM, Sobeh MM, Zayed AA, Al-Domi HA 

(2011) Depression among adults with diabetes in 

Jordan: Risk factors and relationship to blood 

sugar control. J Diabetes Complications 25: 247-

252. 

3. Ceriello A (2003) New insights on oxidative stress 

and diabetic complications may lead to a “causal” 

antioxidant therapy. Diabetes Care 26: 1589-1596. 

4. Giacco F, Brownlee M (2010) Oxidative stress and 

diabetic complications. Circ Res 107: 1058-1070. 

5. Akpan OU, Ewa ID, Etim BE (2013) Ocimum 

gratissimum alleviates derangements in serum and 

biliary bilirubin, cholesterol and electrolytes in 

streptozotocin-induced diabetic rats. Int J Biochem 

Res Rev 3: 171-895. 

6. Byrne CD (2012) Non-alcoholic fatty liver disease, 

insulin resistance and ectopic fat: a new problem in 

diabetes management. Diabetes Med 29: 1098- 

1107. 

7. Ikeda Y, Shimada M, Hasegawa H, Gion T, Kajiyama 

K, et al. (1998) Prognosis of hepatocellular 

carcinoma with diabetes mellitus after hepatic 

resection. Hepatology 27: 1567-1571. 

8. Wang P, Kang D, Cao W, Wang Y, Liu Z (2012) 

Diabetes mellitus and risk of hepatocellular 

carcinoma: a systematic review and meta-analysis. 

Diabetes Metab Res Rev 28: 109-122. 

9. Arkkila PE, Koskinen PJ, Kantola IM, Ronnemaa T, 

Seppanen E, et al. (2001) Diabetic complications are 

associated with liver enzyme activities in people 

with type 1 diabetes. Diabetes Res Clin Pract 52: 113-

118. 

10. Schena FP, Gesualdo L (2005) Pathogenetic 

mechanisms of diabetic nephropathy. J Am Soc 

Nephrol 16: S30-S33. 

11. Tanios BY, Ziyadeh FN (2012) Emerging therapies 

for diabetic nephropathy patients: beyond 

blockade of the renin-angiotensin system. 

Nephron Extra 2: 278-282. 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=


Volume 04 Issue 01-2024 21 

                 

 
 

   
  
 

American Journal Of Biomedical Science & Pharmaceutical Innovation    
(ISSN – 2771-2753) 
VOLUME 04 ISSUE 01 PAGES: 15-21 

SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534) 
OCLC – 1121105677     

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Publisher: Oscar Publishing Services 

Servi 

12. Forbes JM, Coughlan MT, Cooper ME (2008) 

Oxidative stress as a major culprit in kidney disease 

in diabetes. Diabetes 57: 1446-1454. 

 

https://doi.org/10.37547/ajbspi/Volume03Issue03-01
https://scholar.google.co.in/scholar?q=
https://www.mendeley.com/search/?page=1&query=

